Becker's Healthcare January 17, 2025
Erica Carbajal

HHS is investing more than $800 million in vaccine development and manufacturing capacity to strengthen the nation’s response capabilities to emerging infectious disease threats, including bird flu.

Five notes:

  • On Jan. 16, the agency said it intends to invest $211 million to support the development of an RNA-based vaccine technology platform and long-term manufacturing capabilities. The funds will be allocated through the agency’s Administration for Strategic Preparedness and Response.
  • “The funding will allow us to bring the benefits of mRNA vaccine technology to bear against a wider array of emerging threats,” Dawn O’Connell, assistant secretary for preparedness and response at HHS, said in a Jan. 16 news release. “mRNA technology can be faster to develop and easier...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Govt Agencies, Healthcare System, HHS, Patient / Consumer, Provider, Public Health / COVID
Related Articles:
Preparing for the next pandemic with AI
AI could help prepare for the next pandemic, say researchers
Fueled by pandemic frustrations, populist parties are embracing anti-vaccine figures overseas, too
Listen: Why measles is back in the US and what can be done
The Outlook for PEPFAR in 2025 and Beyond

Share This Article